Nightingale expands blood biomarker service with Urine, Spinal Fluid and Cord Blood services

We're delighted to announce that Nightingale is taking further steps towards widespread expansion and development of our services. In addition to our established CE marked blood biomarker service, we'll be offering metabolomics analysis of urine, cerebrospinal fluid (CSF) and umbilical cord blood samples.

The services will deliver comprehensive biomarker data to customers, providing wide-ranging insights into human metabolism and facilitating novel discoveries in biomedical research.

“We are excited to be able to expand our metabolomics offerings in the fall of 2018. Our urine, cerebrospinal fluid (CSF) and umbilical cord blood services will allow us to provide researchers with a pervasive and more complete picture of human health. The ability to compare changes in the metabolic profiles of the different bio-fluids is especially interesting and will further the molecular understanding of health and disease,” said Teemu Suna, CEO and Founder, Nightingale Health.

Nightingale’s quality management system has been certified to EN ISO 13485. Our long-term commitment and continuous investments in quality management have played a central role in our blood biomarker service, and in the development of these new services.

"Our customers trust their valuable sample collections to be assayed with our technology. The quality standard set by EN ISO 13485 is very demanding, but it also guarantees the analysis and results are of the highest level. Quality is a top priority in medical research, and we believe placing it front and center ensures the reliability of novel scientific findings,” continues Suna.

Nightingale’s expanded capabilities enables us to fully cater for researchers working on neurodegenerative conditions, kidney diseases, maternal and fetal health, in addition to those already focused on CVD and diabetes. 

“We’re extremely proud to launch these new services, supporting molecular discoveries via biomarker profiling in cohorts and clinical trials. Nightingale’s novel services utilize high-throughput NMR-based technology, providing cost-effective and scalable solutions. These latest advances will provide new opportunities to researchers for biomarker discovery and translational impact,” said Janna Ranta, Head of Business, Products and Services, Nightingale Health. 

Nightingale’s current blood biomarker analysis service is built upon an unrivalled scientific foundation, with over 100 peer-reviewed publications in leading biomedical journals. In 2017, we achieved recognition that our technology is of a clinical grade standard, receiving CE marking for our blood biomarker analysis service.

“Our latest metabolomics offerings take full advantage of our committed focus to quality standards. This means providing highly repeatable metabolite measures, delivered in absolute concentrations and free of batch effects,” continues Ranta.

The first results from Nightingale’s expanded service will be delivered in the fall, and we're currently taking advanced orders from research institutions worldwide.